BNTC (Benitec Biopharma) Common Stock : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Common Stock?

Benitec Biopharma's quarterly common stock stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Benitec Biopharma's annual common stock declined from Jun. 2021 ($0.00 Mil) to Jun. 2022 ($0.00 Mil) but then stayed the same from Jun. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil).

Benitec Biopharma Common Stock Historical Data

The historical data trend for Benitec Biopharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Common Stock Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

Benitec Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															-	-	-	-	-

Benitec Biopharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Benitec Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Executives

J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Megan Boston	director, officer: Executive Director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira	10 percent owner	18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith	director	C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis	director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks	director, officer: Chief Executive Officer	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000